Market News

Adds an important technology in the filling of injectable beta lactams with sales to the US and European markets.

Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.

The agreements with ViiV Healthcare do not impact BMS’s marketed HIV medicines, including Reyataz, Evotaz, Sustiva and Atripla.

FDA provides GDUFA goal date of 28 March 28 2017

Alliance to provide drug discovery customers access to industry leading ion channel and transporter technologies.

The first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management.

Dublin headquarters central to European and global growth strategy.

Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma.

Expansion reflects critical role of MSD’s Irish sites in wider global network.

The acquisition of InvaGen Pharmaceuticals provides Cipla with about 40 approved ANDAs, 32 marketed products, and 30 pipeline products which are expected to be approved during the next 4 years.

Athenex to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo during the next 10 years.

Patent protects the composition of Rizaport and will be listed in the Orange Book upon approval of the product by FDA.

Designed for use in biotechnological applications, especially for membrane screening and small-volume process development.

Lilly plans to seek permission to appeal the ruling.

Leading CDMO is granted both the WorldStar Award for Vetter-Ject and a 2016 CMO Leadership Award.

Symbiosis Pharmaceutical Services has picked-up several new clients in North America, which has primarily been driven by companies looking for small-scale aseptic manufacturing capabilities to support clinical trials.

Compatibility and testing of nested container and closure systems to help pharmaceutical companies manufacture parenteral medicines.

Combining ThioLogics' site-specific conjugation chemistry with Albumedix's drug delivery platform enables the creation of next-generation albumin drug conjugates.

Responding to the needs of users in the laboratories, Sartorius presents a new range of mechanical pipettes with a perfectly balanced design offering reliability, accuracy and comfortable use.

Pneumatic-powered bottling pick-up grab heads for use with major lines of new or replacement bottling machinery.

Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab.

The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine.

The acquisition allows the company to effectively expand its global presence from operating sites in Japan, Spain, Romania, Canada and the US, to include Brazil.

Practical trainings on globally trending topics.

These meetings will cover aspects of pharmaceutical cleanroom sporicidal disinfection and environmental monitoring best practice during manufacture of pharmaceuticals.

The serialisation of licensed drug products will be a legal requirement for companies in the EU from early 2019.

The pay-for-performance agreement ties the financial terms to how well the drug improves the relative health of Cigna's customers.

Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease.

Pfizer will continue to manage its commercial operations through two distinct businesses — the innovative products business and the established products business — after the completion of the proposed transaction.

Genevac Series 3 HT Evaporator developed to provide a rapid, high-throughput alternative to freeze drying HPLC purification fractions.

MedinCell and Sandoz will develop and commercialize long-acting injectable products based on BEPO technology with a primary focus on oncology.

Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus.

Global API market driven by the rising abbreviated new drug applications and the growth in filing drug master files from several Indian firms, says Transparency Market Research.

The initial laboratory space will amount to 5,500 sq. ft, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.

The collaboration will use Exaxion's computer-based technology to discover novel antigens.

EMA approves Merck's GONAL-f prefilled pen 2.0.

These guidelines primarily focus on recommendations for systems for manufactures of solid dosage forms.

Agreement further supports Teva’s novel biologics development program.

Genentech has won the Process Innovation category for its large-scale, Cell Culture Biologics Drug Substance Plant 2 (CCP2) located in Vacaville, CA.

Price concerns regarding sustainable coatings will be countered by their environmental and durability benefits, finds Frost & Sullivan.

Annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016.

The CDMO will also manufacture 20,000 capsules of the reformulated monepantel solution for the Australian company

Singapore site now provides full clinical supply services.

Capabilities will focus on parenteral dosage forms for biologics, drug conjugates, peptides and small molecules for products for injection or infusion.

Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia against dengue, Sanofi Pasteur is launching a Zika vaccine project.

Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

Thermo Scientific Environmental Chambers use a unique airflow system for advanced temperature control.

The new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies.

Imatinib mesylate is the therapeutic equivalent to Novartis's Gleevec for indications approved by FDA.

This new collaboration will enhance the mission to provide a comprehensive platform to enable the growth of a quality African pharmaceutical industry that competitively contributes to the healthcare needs of Africans.

ATM-AVI is an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

Several projects will be studied to further develop existing local manufacturing collaborations and work on programs to fight chronic and non-communicable diseases.

Additional space will primarily be used to increase laboratory facilities, GMP suites and allocate space for storage of GMP materials.

Agreement for Plendil in China reinforces AstraZeneca’s focus on innovative medicines.

Gary Zieziula to head biopharma business in North America and Marc Horn to lead biopharma business in China.

This award recognizes the company with the highest reviews and ratings on SelectScience.

Redipor prepared media to be supplied directly to customers.

Company to focus on pipeline of Pentarins as a unique and promising approach to treating solid tumour cancers.

Transparency Market Research has announced the publication of a new report, titled "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020".

New website will support clients in developing and implementing entire single-use bioprocesses.

Albumedix strengthens its leading position in albumin-based drug delivery through acquisition of Eleven's Supermin albumin technology.

The new stand-alone company Albumedix will continue to develop albumin-based products and technologies for the pharmaceutical industry.

Recombinant Fc Receptor proteins from AMSBIO are uniquely suitable for pharmaceutical research.

The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages.

The addition of Kalbitor and DX-2930 to Shire's portfolio strengthens its leadership position in hereditary angioedema.

The ideal solution for scaling studies and low volume ultra- and diafiltration operations.

Payer relationship activities are especially important to start early, according to Cutting Edge Information.

A new Consumer Health brand for gastrointestinal upset, starting in January 2016 with Chile.

With the sophisticated developments in microneedle patches, injectors and pre-filled syringes come increasing opportunities for using liquid silicone rubber.

The Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline lacks innovation despite an influx of new therapies, says GBI Research.

The introduction of KANEKA KanCapA expands the portfolio of continuous bioprocessing and chromatography products offered by Pall.

The facility will provide full-service solutions, including project management and clinical supply management, comparator sourcing, secondary packaging and labeling, clinical storage, distribution, and drug return and destruction.

Recommended for monotherapy or adjunctive therapy in the treatment of partial seizures.

Testing services for cosmeceuticals, natural health products and medical marijuana from facilities in Canada.

Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.

New improved antibody oligonucleotide conjugation kit.

Company has acquired Alphamer immuno-therapeutics platform technology.

Court says MSD breached an agreement with Merck by using "Merck" alone either as a trade mark or a name in the UK.

Biogen will manufacture and commercialize Benepali in the EU.

Patient-focused models, improving adherence, and controlling costs all benefit from TD3.

Frost & Sullivan Partner Dorman Followwill comments on one of the disrupting forces that are transforming the healthcare markets.

The deal is based on milestone payments during 2016 and royalty payments per sold dose. Product launch is expected during 2017.

Oral Route, pulmonary, topical, implantable, injectable, transdermal and transmucosal route analysis.

Collaboration partners to strengthen research in psychiatric diseases.

The so-called method of use patent covers the use of CD95 ligand inhibitors, such as APG101, for the treatment of glioblastoma.

Increased hiring of big data experts and data scientists could help to revitalise the pharmaceutical sector, according to NonStop Recruitment.

Suite of reports provide readers with a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish.

Recall due to a potential defect with the dosage cup.

Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.

Lonza adds two 1000-L single-use bioreactor systems to its current mammalian manufacturing capacity.

Gilles Cottier to lead the company’s PDS business.

The treatment pipeline for Parkinson's disease offers a markedly more promising landscape from the current market, says GBI Research.

Research and Markets has announced the addition of the "Global Pharmaceutical Packaging Market 2016–2020" report to their offering.

Company generates unique monoclonal antibodies that selectively inhibit the supracellular activation of latent TGF-beta 1 in the immune system.

Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020.

The global breast cancer therapeutics market will increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, says GBI Research.

Yves Buelens has been the plant manager for the Kaysersberg facility since 2014.

Final approval of the company's application is subject to the resolution of minor outstanding topics, such as the use of appropriate language in the product labeling.

The assets will broaden AmpliPhi's IP portfolio and speed the development of its phage therapies

GlobalData report states that the leading driver of this growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including BMS's Orencia, J&J’s Remicade, GSK’s (GSK) Benlysta and Nucala, and Roche’s A...

Genomics’ proprietary statistical analysis tools and integrated multi-phenotype database to be used to support R&D at Vertex Pharmaceuticals.

Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing.

Acquisition adds global rights to novel NDSTM platform topical delivery technology and ANT-1207, investigational botulinum toxin type A product.

Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products.

Recall issued as a result of a customer reporting an incorrect barcode on the primary bag labeling.

Thousands of patients now using "smart" AdhereTech pill bottle to improve medication adherence.

Novartis plans to launch the next generation connected Breezhaler in 2019.

MannKind is now reviewing its strategic options for Afrezza

Innovative therapies for some skin diseases have stimulated renewed interest in this market among major pharma companies.

Indonesia is poised to become a production base for overseas and local manufacturers of medicines.

Acerus's immediate focus is to find a new Natesto partner in the US.

The issuance of the new patent will expand Tribute's intellectual property protection for Cambia, currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.

The expansion of the refrigerated container fleet will support the growing demand for ZIMonitor, ZIM's premium reefer cargo tracking service.

The three companies will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer.

The new business venture, to be owned 51% by Teva and 49% by Takeda, will consist of Teva Takeda Pharma and Teva Takeda Yakuhin.

Collaboration between NIH and Tetra Discovery Partners leads to development of treatment that may affect cognition.

The Guide is intended to assist both customers and suppliers in efficiently managing the initiation, negotiation, implementation, and ongoing maintenance of quality agreements.